ATE320419T1 - Indazolderivate mit 5-ht2-rezeptor-aktivität - Google Patents

Indazolderivate mit 5-ht2-rezeptor-aktivität

Info

Publication number
ATE320419T1
ATE320419T1 AT99943082T AT99943082T ATE320419T1 AT E320419 T1 ATE320419 T1 AT E320419T1 AT 99943082 T AT99943082 T AT 99943082T AT 99943082 T AT99943082 T AT 99943082T AT E320419 T1 ATE320419 T1 AT E320419T1
Authority
AT
Austria
Prior art keywords
alkyl
disorders
alkoxy
hydrogen
treatment
Prior art date
Application number
AT99943082T
Other languages
English (en)
Inventor
David Reginald Adams
Jonathan Mark Bentley
Jonathan Richard Anthon Roffey
Richard John Hamlyn
Ashley Roger George
Original Assignee
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd
Application granted granted Critical
Publication of ATE320419T1 publication Critical patent/ATE320419T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT99943082T 1998-09-01 1999-09-01 Indazolderivate mit 5-ht2-rezeptor-aktivität ATE320419T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9819032.5A GB9819032D0 (en) 1998-09-01 1998-09-01 Chemical compounds IV

Publications (1)

Publication Number Publication Date
ATE320419T1 true ATE320419T1 (de) 2006-04-15

Family

ID=10838164

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99943082T ATE320419T1 (de) 1998-09-01 1999-09-01 Indazolderivate mit 5-ht2-rezeptor-aktivität

Country Status (10)

Country Link
US (1) US6552062B1 (de)
EP (1) EP1129078B1 (de)
JP (1) JP2002525280A (de)
AT (1) ATE320419T1 (de)
AU (1) AU5636799A (de)
CA (1) CA2341612A1 (de)
DE (1) DE69930397T2 (de)
ES (1) ES2260931T3 (de)
GB (1) GB9819032D0 (de)
WO (1) WO2000012481A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9820767D0 (en) * 1998-09-23 1998-11-18 Cerebrus Ltd Chemical compounds VIII
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
CN1450994A (zh) * 2000-03-17 2003-10-22 爱尔康公司 用于治疗青光眼的6－羟基－吲唑衍生物
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
DK1337518T3 (da) 2000-11-20 2009-10-19 Biovitrum Ab Publ Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
JP2005506280A (ja) 2000-12-20 2005-03-03 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー アリールおよびアミノアリール置換セロトニン受容体アゴニストおよびアンタゴニストリガンド
AU2002360819A1 (en) * 2001-12-28 2003-07-24 Bayer Corporation Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
TW200400177A (en) * 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
AU2003243089B2 (en) 2002-06-19 2010-01-07 Biovitrum Ab (Publ) Novel compounds, their use and preparation
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
EP2400300A1 (de) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Screeningverfahren von Mitteln zur Prävention/Behandlung von stressbedingter Harninkontinenz
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0232059A (ja) * 1988-07-18 1990-02-01 Kyowa Hakko Kogyo Co Ltd インダゾール誘導体
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
TW270114B (de) * 1993-10-22 1996-02-11 Hoffmann La Roche
JPH08225535A (ja) * 1994-11-15 1996-09-03 Dai Ichi Seiyaku Co Ltd インダゾール誘導体
AU5343298A (en) * 1997-01-13 1998-08-03 Yamanouchi Pharmaceutical Co., Ltd. 5-ht2c receptor agonists and aminoalkylindazole derivatives

Also Published As

Publication number Publication date
WO2000012481A2 (en) 2000-03-09
US6552062B1 (en) 2003-04-22
CA2341612A1 (en) 2000-03-09
ES2260931T3 (es) 2006-11-01
JP2002525280A (ja) 2002-08-13
EP1129078B1 (de) 2006-03-15
WO2000012481A3 (en) 2000-06-08
AU5636799A (en) 2000-03-21
DE69930397D1 (de) 2006-05-11
GB9819032D0 (en) 1998-10-28
EP1129078A2 (de) 2001-09-05
DE69930397T2 (de) 2006-11-30

Similar Documents

Publication Publication Date Title
HK1034967A1 (en) Pyroloindoles, pyridoindoles and azepinoindoles as5-ht2c agonists.
ATE320419T1 (de) Indazolderivate mit 5-ht2-rezeptor-aktivität
PT1109809E (pt) Pirroloquinolinas para tratamento da obesidade
WO2000017170A3 (en) N1-substituted benzopyrazoles as inhibitors of 5-ht2 receptors
WO2000012482A3 (en) Indazole derivatives with 5-ht2 receptor activity
DE60002554D1 (de) Pyrazino(aza)indolderivate
AR029815A1 (es) Derivados aza-indolicos, un proceso para su preparacion, composicion farmaceutica, un metodo para su elaboracion y el uso de dichos derivados para la manufactura de un medicamento
NO20055655L (no) Anvendelse av azetidinkarboksamidderivater i terapi
HUP0202477A2 (hu) Ftalazinszármazékok alkalmazása
ATE348817T1 (de) 5-cyano-2-aminopyrimidine derivate
BR0013307A (pt) Compostos quìmicos de indol, seus usos e métodos de preparação, método de tratamento, composição e método de fabricação de uma composição farmacêutica que os contêm
WO2001012602A8 (en) Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands
GEP20125538B (en) 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
GB0018272D0 (en) Chemical compounds IV
GB9901691D0 (en) Chemical compounds
NZ337048A (en) Use of N-[1-methyl-(substituted phenyl)ethyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide derivatives to treat prostate cancer
AR029353A1 (es) Un compuesto derivado de pirazinoindol, uso del mismo, una composicion farmaceutica que lo comprende y un metodo para la fabricacion de dicha composicion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties